the aid library

LIST OPTIONS

Filter

10972

Sort by:

Direction:

Download (562)

View PDF (1195)

Zika Strategic Response Plan Quarterly update, October 2016

World Health Organization WHO (2016) C_WHO

Download (99)

View PDF (838)

Antimicrobial resistance in the WHO African region: current status and roadmap for action

Essack S.Y., A.T. Desta, R.E. Abotsi et al. Journal of Public Health (2016) C2

The escalating antimicrobial resistance (AMR) pandemic is a global public health threat with extensive health, economic and societal implications. Resistance emerges because of selection pressure from rational and indiscriminate antimicrobial use in human health as well as in the veterinary, agricul... more

Download (155)

View PDF (300)

Promotion, prevention and protection: interventions at the population- and community-levels for mental, neurological and substance use disorders in low- and middle-income countries

I. Petersen; , S. Evans‐Lacko; M. Semrau; et al. International Journal of Mental Health Systems; BioMed Central (2016) CC

Petersen et al. Int J Ment Health Syst (2016) 10:30 DOI 10.1186/s13033-016-0060-z

Download (183)

View PDF (261)

WHO Preventing suicide: a community engagement toolkit Pilot version 1.0
recommended

World Health Organization WHO (2016) C_WHO

Communities can play a critical role in suicide prevention. Facilitating community engagement in suicide prevention is an important task. The toolkit is a step-by-step guide for communities to engage in suicide prevention activities and have ownership of the process and keep efforts sustained. It is... more

Download (549)

View PDF (2677)

Guideline on when to start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

Elaine Abrams, Tsitsi Apollo, Janet Bhila et al. World Health Organization WHO (2015) C_WHO

The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ... more

Download (620)

View PDF (3344)

Promoting Rights and Community Living for Children with Psychosocial Disabilities
recommended

World Health Organization (WHO) (2015) C_WHO

Download (1525)

View PDF (2434)

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
recommended

World Health Organization (2015) C_WHO

The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of n... more

Download (1244)

View PDF (2851)

Standard Operating Procedures for Contact Tracing and Follow up during Ebola Virus Disease Outbreak

Ministry of Health and Sanitation Sierra Leone (2014)

Download (123)

View PDF (135)

Make hospitals safe in emergencies

World Health Organization (2009)

Download (116)

View PDF (148)

Behavioural Surveillance - Surveillance of HIV Risk Behaviours

United States Department of Health and Human Services; Centers for Disease Control and Prevention (HHS-CDC); Global AIDS Program (GAP); et al. United States Department of Health and Human Services; Centers for Disease Control and Prevention (HHS-CDC); Global AIDS Program (GAP); et al. (2009) C2

Participant Manual October 2009

Download (26)

View PDF (17)

Guideline on management of pneumonia and diarrhoea in children up to 10 years of age
New

World Health Organization WHO (2024) C_WHO

Pneumonia and diarrhoea account for 23% of under-five mortality and were responsible for an estimated 1.17 million deaths in children under five globally. Furthermore, pneumonia and diarrhoea were responsible for 18% of mortality in children 5–9 years of age, resulting in an estimated 86 000 preve... more

Download (112)

View PDF (93)

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani... more

Download (35)

View PDF (43)

Serie «de la intención a la acción»: Reflexiones regionales. Análisis de las consultas regionales informales con personas que viven con enfermedades no transmisibles y trastornos mentales 2023

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

El presente informe incluye análisis de consultas informales en cinco de las regiones de la OMS: la Región de África, la Región de las Américas (donde se realizaron consultas separadas para el Caribe y América del Norte, y para América Latina), la Región de Asia Sudoriental, la Región de Eu... more

Download (60)

View PDF (45)

Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map-english and french

World Health Organisation (WHO) (2024) C_WHO

This report on global leishmaniasis surveillance follows those published in 2016–2023.2–6 Six indicators of leishmaniasis are publicly available from the Global Health Observatory (GHO).7 In addition to the GHO, country profiles with up to 30 indicators are published, with detailed data received... more

Download (54)

View PDF (36)

Management of type 2 diabetes in adults

Department of Health: Republic of South Africa (2014) CC2

Diabetes is a major public health problem. The rising incidence of Diabetes Type 2 is related to the effects of urbanization and unhealthy lifestyles. Research studies show that healthy eating and regular physical activity can prevent or delay the onset of Diabetes Type 2, even in high-risk individu... more

Download (592)

View PDF (320)

Guideline for the pharmacological treatment of hypertension in adults
recommended

World Health Organization WHO (2021) C_WHO

The recommendations cover the level of blood pressure to start medication, what type of medicine or combination of medicines to use, the target blood pressure level, and how often to have follow-up checks on blood pressure. In addition, the guideline provides the basis for how physicians and other h... more

Download (67)

View PDF (118)

Implementation toolkit for accessible telehealth services

World Health Organisation (WHO) (2024) C_WHO

The Implementation toolkit for accessible telehealth services provides practical guidance to support governments, industry partners, health service providers and civil society groups in the use and implementation of the WHO-ITU Global standard for accessibility of telehealth services. The toolkit is... more

Download (155)

View PDF (167)

WHO ZIMBABWE CHOLERA OUTBREAK UPDATE

World Health Organization WHO (2023) C_WHO

After years of relative calm, Zimbabwe has been grappling with a cholera outbreak since 12 February 2023. This resurgence is not an isolated incident, as 10 more countries (Malawi, Mozambique, Somalia, Kenya, Ethiopia, Zambia, South Sudan, Burundi, Tanzania and South Africa) in Eastern and Southern ... more

Download (169)

View PDF (363)

WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer

World Health Organization WHO (2020) C_WHO

Globally, 311,000 women die of cervical cancer every year, 85 percent of them in resource limited regions of the world. To address this grave threat to women, the WHO made a call to action in 2018, resulting in accelerated plans to improve cervical cancer control under the elimination threshold w... more

Download (280)

View PDF (375)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO Preventing suicide: a community engagement toolkit Pilot version 1.0 recommended

Promoting Rights and Community Living for Children with Psychosocial Disabilities recommended

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection recommended

Guideline on management of pneumonia and diarrhoea in children up to 10 years of age New

Guideline for the pharmacological treatment of hypertension in adults recommended

WHO Preventing suicide: a community engagement toolkit Pilot version 1.0
recommended

Promoting Rights and Community Living for Children with Psychosocial Disabilities
recommended

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
recommended

Guideline on management of pneumonia and diarrhoea in children up to 10 years of age
New

Guideline for the pharmacological treatment of hypertension in adults
recommended